Lv1
90 积分 2023-08-04 加入
Translational Insights and Overall Survival in the U31402-A-U102 Study of Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC
1个月前
已完结
Efficacy of depatuxizumab mafodotin (ABT-414) in preclinical models of head and neck cancer
2个月前
已完结
Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumors
3个月前
已完结
Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours
3个月前
已完结
SKYSCRAPER-03: A Phase III, Open-Label, Randomized Study of Atezolizumab Plus Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable, Stage III NSCLC Who Have Not Progressed After Platinum-Based Concurrent Chemoradiation
4个月前
已完结
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study
4个月前
已完结
Twenty-five years with HER2 targeted therapy
4个月前
已完结
Antibody-drug conjugates in lung and breast cancer: Current evidence and future directions – a position statement from the ETOP IBCSG Partners Foundation
4个月前
已完结
Unlocking the potential of bispecific ADCs for targeted cancer therapy
4个月前
已完结
Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: First-in-human dose-escalation study
4个月前
已完结
皖公网安备34019202002308
